

---

**Subject:** Media advisory

---

**THERATECHNOLOGIES HOLDS ANNUAL AND SPECIAL MEETING OF  
SHAREHOLDERS**

MONTREAL (Quebec), May 16, 2011—Theratechnologies Inc. (TSX:TH) (“Theratechnologies”) will hold its annual and special meeting of shareholders in Montreal this Wednesday, May 18, at 10 am.

**Datebook**

**What:** Annual and special meeting of shareholders of Theratechnologies

**When:** Wednesday, May 18, at 10 am

**Where:** Sheraton Montreal, 1201 René-Lévesque West Blvd., Montréal

**Who:** Mr. Paul Pommier, Chairman of the Board  
Mr. Luc Tanguay, Senior Executive Vice-President and Chief Financial Officer

Please note that Mr. John-Michel Huss will not be able to attend the annual and special meeting of shareholders. His absence is due to ophthalmic surgery that he will undergo to treat a retinal detachment in his right eye. His doctors expect a short recovery; however, the surgery cannot be delayed without causing additional risk to Mr. Huss.

**About Theratechnologies**

Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Its first product, *EGRIFTA*<sup>™</sup> (tesamorelin for injection), was approved by the United States Food and Drug Administration in

November 2010. To date, *EGRIFTA*<sup>™</sup> is the only approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

*EGRIFTA*<sup>™</sup> is currently marketed in the United States by EMD Serono pursuant to a collaboration and licensing agreement executed in October 2008. In addition, the Corporation has signed distribution and licensing agreements with a subsidiary of Sanofi-aventis granting them the exclusive commercialization rights for *EGRIFTA*<sup>™</sup> for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy in Latin America, Africa and the Middle East and with Ferrer Internacional S.A. granting them the exclusive commercialization rights for *EGRIFTA*<sup>™</sup> for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy in Europe, Russia, South Korea, Taiwan, Thailand and certain central Asian countries.

#### **Additional Information about Theratechnologies**

Further information about Theratechnologies is available on the Corporation's website at [www.theratech.com](http://www.theratech.com). Additional information about the Corporation is also available on SEDAR at [www.sedar.com](http://www.sedar.com).

-30-

#### **INFORMATION:**

Roch Landriault

514-843-2345

[rlandriault@national.ca](mailto:rlandriault@national.ca)